medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose V...
FDA Drug Recall #D-0185-2025 - Class II, December 18, 2024
Recall Summary
| Recall Number | D-0185-2025 |
| Classification | Class II - Moderate risk |
| Date Initiated | December 18, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Eugia US LLC |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 19872 vials |
Product Description
medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: Eugia US LLC, NJ 08520 NDC 55150-329-01 Shipper label: medroxyPROGESTERone Acetate Injectable Suspension, USP, 150 mg per mL, Distributed by: Eugia US LLC, NJ, Manufactured by: Eugia Pharma Specialties Limited, India
Reason for Recall
CGMP Deviations
Distribution Pattern
Nationwide in the US
Lot / Code Information
Lot No.: 1MP24069, Exp.: 08/2026
Other Recalls from Eugia US LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0552-2026 | Class III | Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20... | May 18, 2026 |
| D-0472-2025 | Class II | Gentamicin Injection, USP, (PEDIATRIC), 20 mg p... | May 29, 2025 |
| D-0390-2025 | Class II | Tirofiban Hydrochloride Injection 12.5 mg/250 m... | Apr 21, 2025 |
| D-0389-2025 | Class II | Tirofiban Hydrochloride Injection 5 mg/100 mL (... | Apr 21, 2025 |
| D-0363-2025 | Class II | Testosterone Cypionate Injection, USP, CIII, 20... | Apr 10, 2025 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice, the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful, in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.